Can we define breast cancer HER2 status by liquid biopsy?

Authors :: Di Cosimo S
De Marco C
Silvestri M
Busico A
Vingiani A
Pruneri G
Cappelletti V
Source :: International review of cell and molecular biology [Int Rev Cell Mol Biol] 2023; Vol. 381, pp. 23-56. Date of Electronic Publication: 2023 Sep 04.
Publication Year :: 2023
Abstract: Human Epidermal growth factor Receptor 2 (HER2) assessment is crucial for breast cancer treatment. Therapeutic decisions for recurrent cases often rely on primary tumor status. However, mounting evidence suggests that tumors show dynamic changes and up to 10% of breast cancer modify their initial status during progression. It is still debated whether these changes reflect a biological evolution of the disease or are secondary to primary tumor heterogeneity. Certainly, repeating HER2 assessment during breast cancer trajectory is important for the increasing availability of effective anti-HER2 drugs. In response to this need, circulating biomarkers such as circulating tumor cells (CTCs) and cell-free circulating tumor DNA (ctDNA) offer the potential to safely and repeatedly assess HER2 status over time. This chapter outlines current methods for testing HER2 in CTCs and ctDNA, and reviews clinical trials evaluating its prognostic and predictive value in patients with breast cancer, as well as recent advances in the field.<br /> (Copyright © 2023. Published by Elsevier Inc.)